*         Pulmonary delivery of anti-viral Nanobodies® gives extended
  protection against viral infection in vivo
*         In vivo proof of concept for its novel proprietary
  half-life extension technology


GHENT, Belgium,  14 January 2009  - Ablynx [Euronext Brussels: ABLX],
a pioneer in the  discovery and development  of Nanobodies®, a  novel
class of antibody-derived therapeutic  proteins, announced today  two
significant advances  achieved with  its Nanobody®  platform. In  the
first,  it  has  shown  that  anti-viral  Nanobodies®  give  extended
protection against viral infection in  vivo when administered via  an
intrapulmonary route. In the second, Ablynx has demonstrated in  vivo
proof of  concept  for  a proprietary  novel  half-life(*)  extension
technology  which  allows  the   half-life  of  its   Nanobody®-based
therapeutics to be tailored depending on the disease indication.

Pulmonary delivery of Nanobodies®
Ablynx has demonstrated that  anti-viral Nanobodies® protect  against
signs of viral infection and presence of active virus when  delivered
via an intrapulmonary route. Following a single administration of the
Nanobodies® via the lungs, neutralization  of virus was observed  for
at least 72 hours.

Additionally, Ablynx  has shown  that  Nanobodies® are  suitable  for
systemic delivery(**) via the  lungs. Their extended  bioavailability
is increased  by  a  factor  of  five  to  ten  times  compared  with
intravenous administration.

Ablynx is also investigating other alternative delivery  technologies
for  its  Nanobodies®  including   oral  to  systemic  delivery   and
needleless administration.

Novel proprietary half-life extension technology
Ablynx  has  access  to  several  different  methods  to  tailor  the
half-life of its Nanobodies® depending on the desired characteristics
of the therapeutic  drug candidate  and the  indication. The  Company
announced today  that  they have  discovered  and developed  a  novel
proprietary half-life extension technology  and demonstrated in  vivo
results which show considerable  potential to significantly  increase
the half-life for its Nanobodies® in humans.


Please see link below for the complete version of this press release

For more information, please contact:
College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John McIntyre
t:   +44 (0)20 7866 7857
f:   +44 (0)20 7866 7900
e:  ablynx@collegehill.com

Ablynx:
Dr. Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:  eva-lotta.allan@ablynx.com


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.
http://hugin.info/137912/R/1282211/286864.pdf


Copyright © Hugin AS 2009. All rights reserved.